MedTrace Logo

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

NCT01121120 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-12-08

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.

Conditions

Interventions

DRUG

TXA127

300mcg/kg/day, administered subcutaneously for up to 28 days

DRUG

Placebo

300mcg/kg/day administered subcutaneously for up to 28 days

Sponsors & Collaborators

  • Constant Therapeutics LLC

    collaborator INDUSTRY

  • Tarix Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Michael Schuster, MD · Stony Brook university Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121120 on ClinicalTrials.gov